Gastro Health, a leading national medical group specializing in digestive and liver health, has announced a strategic partnership with Echosens, the global leader in non-invasive liver assessment, to advance the identification and management of patients at risk for metabolic liver disease.
"Liver health is an increasingly important part of how we identify and manage patients with metabolic disease, and gastroenterologists are uniquely positioned to help lead that care," said Alan Oliver, CEO of Gastro Health. "Echosens brings an established technology, deep clinical experience and the support needed to help us scale while maintaining a physician-led approach to how we identify, risk-stratify and manage patients.”
Through the partnership, Gastro Health will integrate FibroScan® across its network, providing patients with faster, non-invasive liver assessment at the point of care. This helps physicians identify risk earlier, determine appropriate next steps, and monitor patients over time—without the need for more invasive procedures.
Key benefits for patients include:
"Patients with obesity, diabetes, and other metabolic risk factors frequently have an increased risk of liver disease, yet it often goes undiagnosed until later stages," said Dr. Jose Lavergne, Medical Director of Clinical Quality at Gastro Health. "Having access to non-invasive liver assessment within the gastroenterology setting gives physicians another important tool to identify risk earlier, educate patients and determine the most appropriate next steps."
The collaboration supports Gastro Health's broader effort to build a systematic, enterprise-wide approach to liver disease management, connecting clinical care with research and real-world evidence to improve patient outcomes at scale.
“FibroScan® provides a practical, evidence-based way for physicians to bring objective liver health assessment directly into the clinical setting,” said Jon Gingrich, CEO of Echosens North America. “We are proud to partner with Gastro Health as they build a scalable, physician-led approach to liver and metabolic health. Integrating non-invasive liver assessment into routine care has the potential to create meaningful value for both physicians and patients.”
For more details, please see Echosens' release.
About Gastro Health: Gastro Health is one of the leading gastroenterology platforms in the United States supporting practices in Alabama, Florida, Maryland, Massachusetts, Ohio, Virginia, and Washington – with over 650 providers and 150 locations consisting of medical offices, infusion centers, imaging services, and a specialty pharmacy. Additionally, Gastro Health owns and operates endoscopy centers in five of the seven states and operates pathology and anesthesia services. Gastro Health strives to provide outstanding medical care and an exceptional healthcare experience. The Gastro Health care teams utilize technology, clinical expertise, and compassionate care to provide a personalized approach to digestive health and overall wellness.
About Echosens: A pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 5,600 peer-reviewed publications, including nearly 220 international guidelines. https://www.echosens.com/